Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm
On August 28 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. On Tuesday, September 4 the company presents to investors at Aktiekvällen in Gothenburg, followed by further events in Stockholm.
"We’re developing the world's first dedicated treatment for PMDD, the severest form of PMS," says Peter Nordkild, CEO of Asarina Pharma. “PMDD is a painful condition that impacts 1-in-20 women of a fertile age worldwide—as well as their families, friends and co-workers. I look forward to presenting our clinical data, and the major market potential for investors, in our two largest cities.”
PMDD (Premenstrual Dysphoric Disorder) is characterized by severe physical and emotional symptoms in the later part of the menstrual cycle. Current treatments provide only moderate relief of symptoms for most women, and many discontinue treatment to avoid side-effects.
"Sepranolone, the treatment we’re developing, has reduced PMDD symptoms by 80 percent in a clinical study," says Nordkild, “and this largely without side effects.”
Ongoing Phase IIB study, goal to launch on market early 2020’s
A major Phase IIB study is currently underway in Europe, to verify the efficacy and safety of Sepranolone. Following that Asarina Pharma aims to launch the treatment onto the market as soon as 2023. Next year, 2019, the company begins a Phase IIA trial of Sepranolone as a treatment for menstrual migraine, another common, but rarely mentioned, condition that affects 1-in-5 women of a fertile age.
"The conditions are right for us to launch a first-in-class treatment onto a global market,” says Nordkild. “Given that effective competing treatments are almost non-existent, I hope that small and large investors alike are drawn to this extraordinary business opportunity, helping women worldwide affected by these disorders remain in control of their lives.”
Asarina Pharma will be is presented by Otto Skolling, Chief Business Officer at Aktiekvällen Göteborg, which is organized by Aktiespararna in cooperation with Erik Penser Bank on September 4, 17.00-21.00, at Elite Park Avenue at Kungsportsavenyn 38. Register at Aktiespararna.se.
Information about future investment events will be announced later.
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: [email protected]
About Asarina Pharma AB
We are a Swedish biotech company developing Sepranolone: the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD, menstrual migraine and menstrual epilepsy. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women’s Health.
Transaction with shares in Curasight A/S made by managerial employee
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides imp...
NFL BIOSCIENCES : PARTICIPATION À LA H.C.WAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques pour le traitement des dépendances et addictions, annonce qu’Ignacio Faus, Directeur général de NFL Biosciences a été invité à présenter à la conférence « H.C.WAINWRIGHT 1...
NFL BIOSCIENCES TO PRESENT AT THE H.C.WAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that Ignacio Faus, Chief Executive Officer of NFL Biosciences, has been invited to present in the H.C. WAINWRIGHT 1st ANNUAL MENTAL HE...
Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST
A significant event for Brain+ as DiPA can provide reimbursement coverage for the first Cognitive Stimulation Therapy (CST) product, expected to be launched in Germany in 2023 The CST product fits well with the requirements of the DiPA reimbursement pathway. The goal of the DIPA is to reimburse...